尿激酶纤溶酶原激活物、可溶性程序性死亡配体1对肝癌切除术后患者临床预后的评估

Evaluation of uPA and sPD-L1 in clinical prognosis of patients after liver cancer resection

目的:分析尿激酶纤溶酶原激活物、可溶性程序性死亡配体1在肝癌患者中的表达,评估其对肝癌切除术后患者的临床预后。方法:选取2014年1月至2016年6月肝癌患者122例(试验组),另选健康体检者80例(对照组)。检测两组人群血清uPA、sPD-L1含量;分析血清uPA、sPD-L1表达水平与肝癌患者临床病理特征及预后的关系;分析血清uPA、sPD-L1对原发性肝癌不良预后的预测价值。结果:试验组患者血清uPA、sPD-L1水平高于对照组(P<0.05)。肝癌患者的不同分化程度、TNM分期、淋巴结转移和门静脉癌栓的血清uPA、sPD-L1相比,差异均有统计学意义(P<0.05)。肝癌死亡患者血清uPA、sPD-L1水平高于存活患者(P<0.05)。Kaplan-Meier生存曲线分析示:uPA、sPD-L1高表达的肝癌患者生存率低于uPA、sPD-L1低表达患者(P<0.05)。结论:肝癌患者血清uPA、sPD-L1明显升高,uPA、sPD-L1升高与肝癌患者病情严重程度及预后不良有关,可作为肝癌患者临床预后的评估指标。

Objective:To analyze the expression of urokinase plasminogen activator(uPA)and soluble programmed death ligand 1(sPD-L1)in patients with liver cancer,and to explore its clinical value for poor prognosis of patients with liver cancer after surgery.Methods:From January 2014 to June 2016,122 patients with liver cancer treated(experimental group)and 80 healthy subjects(control group)were selected.compared of serum uPA and sPD-L1 levels in two groups;the relationship between serum uPA,sPD-L1,clinicopathological characteristics and prognosis of patients with liver cancer.To analyze the predictive value of serum uPA and sPD-L1 on the poor prognosis of primary liver cancer.Results:The serum uPA and sPD-L1 levels in the experimental group were higher than those in the control group(P<0.05).Compared serum uPA and sPD-L1 in patients with liver cancer in different degrees of differentiation,TNM stage,lymph node metastasis and portal vein tumor thrombus,the differences were statistically significant(P<0.05).The serum uPA and sPD L1 levels in patients with liver cancer death were higher than those in surviving patients(P<0.05).Kaplan Meier survival curve analysis showed that the survival rate of patients with high expression of uPA and sPD-L1 was lower than that of patients with low expression of uPA and sPD-L1(P<0.05).Conclusion:The serum uPA and sPD-L1 levels of patients with liver cancer are significantly increased.The increase of uPA and sPD-L1 is related to the severity of disease and poor prognosis in liver cancer,which could be used as an index for evaluating the clinical prognosis of liver cancer patients.